Table 1.
Selected studies on salvage surgery and first-line therapy for stage III/IV NSCLC.
| Stage | Modality | OS (%), MST (m) | mPFS (m) | RR (%) | Ref. |
|---|---|---|---|---|---|
| Stage III | CRT only | 5-y OS: 5–25, 26 | - | - | [6,15] |
| CRT → ICI | 3-y OS: 66.3, 38.4 | 16.8 | 28.4 | [22] | |
| CRT → SS | 5-y OS: 20–75, 9–46 | - | - | [18] | |
| RT → SS | N.A., 13.6–82.7 | - | - | [21] | |
| Stage IV | EGFR-TKI only(osimertinib) | 1.5-y OS: 83, N.A. | 8.9 | 80 | [28] |
| ICI only(pembrolizumab) | 0.5-y OS: 80.2, 14–19.2 | 10.3 | 44.8 | [33] | |
| ICI + CT | 2-y OS: 45.7, 15.9–22 | 6.4–9 | 48 | [34,35,36] | |
| EGFR-TKI → SS | 3-y OS: 50, 32 | - | - | [29] | |
| ICI → SS | 2-y OS: 77, N.A. | - | - | [37] | |
| (Oligometastasis) | CT + RT (all lesions) | 5-y OS: 7.6, 18 | - | - | [24] |
| Surgery (all lesions) → CT | 5-y OS: 21.1, 48 | - | - |
CRT: chemoradiotherapy, CT: chemotherapy, EGFR-TKI: epidermal growth factor receptor-tyrosine kinases inhibitor, ICI: immune-checkpoint inhibitor, mPFS: median progression-free survival, MST: median survival time, N.A.: not available, NSCLC: non-small cell lung cancer, OS: overall survival, Ref.: reference, RR: response rate, RT: radiotherapy, SS: salvage surgery, y: year.